The efficacy and good safety profile of low-dose IL-2 (aldesleukin) has been confirmed in a single-center clinical trial initiated in 2014; the study group comprised 12 patients with active SLE not responding to treatment with at least two classic drugs, such as corticosteroids, antimalarials, azathioprine, or mycophenolate mofetil [109]. This evidence concerns the gene IL2 and systemic lupus erythematosus.